Imaging Drug Resistance in Juvenile Myoclonic Epilepsy with MRI-derived Cortical Markers
Bernardo Crespo Pimentel,Giorgi Kuchukhidze,Fenglai Xiao,Lorenzo Caciagli,Julia Höfler,Lucas Rainer,Martin Kronbichler,Christian Vollmar,John S Duncan,Eugen Trinka,Matthias Koepp,Britta Wandschneider
DOI: https://doi.org/10.1101/2023.12.03.23298783
2023-01-01
Abstract:Juvenile myoclonic epilepsy (JME) is the most common idiopathic generalized epilepsy (IGE) syndrome and can present a significant clinical challenge due to lack of seizure control and concomitant neuropsychological impairment. Its underlying mechanisms remain poorly understood. MRI studies have described structural changes in individuals with IGE syndromes but have so far not identified a distinct structural profile associated with drug resistant IGE. In this cross-sectional case-control neuroimaging analysis we included 79 participants with JME recruited at two European epilepsy centres, 43 of whom were drug resistant, as defined by recurrent seizures in the last 12 months despite adequate trials of at least two antiseizure medications (ASM), a drug sensitive group ( n =37), and 78 healthy controls. Participants underwent T1-weighted MRI and a comprehensive neuropsychological test battery including measures within two different domains: verbal memory and executive function. We performed vertex-wise measurements of cortical thickness and neurodevelopmental cortical measures, i.e. white matter surface area and local gyrification index (LGI), through a surface-based framework with subsequent correction of scanner-related effects. Group comparisons (family-wise error (FWE) corrected at p <0.05, family-wise error corrected) showed an increase of surface area in prefrontal, cingulate and temporal regions with left-sided predominance accompanied by increased LGI in the left temporal lobe in drug-resistant compared to drug-responsive individuals with JME. Performance on executive function in participants with drug resistant JME was reduced compared to drug sensitive JME ( p Bonferroni <0.01) and controls ( p Bonferroni <0.001). Impaired executive function correlated with increased surface area in medial prefrontal and temporal cortical regions ( r < -0.75, p <0.01) after adjusting for disease duration and total ASM load. In conclusion, we identified a cognitive-developmental profile in drug resistant JME characterized by left-weighted changes in surface area and cortical folding complexity, the extent of which correlates with the degree of executive dysfunction. Our results shed further light onto the pathophysiological mechanisms of JME and suggest a neurodevelopmental/network basis for both drug refractoriness and cognitive impairment. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This research was funded by the Austrian Science Fund (Fonds zur Foerderung der Wissenschaftlichen Forschung, project number KLI 969) awarded to E.T, and from Wellcome Trust and Henry Smith Charity (20133416) awarded to M.J.K. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of the UCL Queen Square Institute of Neurology and University College London Hospitals gave ethical approval for this work. Ethics committee of the State of Salzburg (Ethikkommission fuer das Bundesland Salzburg) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The data supporting the findings of this study are available from the corresponding author upon reasonable request. Study datasets are not made publicly available due to ethical and data protection restrictions.